- Home
- VERI vs NGNE Comparison
VERI vs NGNE Comparison
Compare VERI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- NGNE
- Stock Information
- Founded
- VERI 2014
- NGNE 2003
- Country
- VERI United States
- NGNE United States
- Employees
- VERI N/A
- NGNE N/A
- Industry
- VERI EDP Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- VERI Technology
- NGNE Health Care
- Exchange
- VERI Nasdaq
- NGNE Nasdaq
- Market Cap
- VERI 438.8M
- NGNE 426.6M
- IPO Year
- VERI 2017
- NGNE N/A
- Fundamental
- Price
- VERI $6.50
- NGNE $26.68
- Analyst Decision
- VERI Strong Buy
- NGNE Strong Buy
- Analyst Count
- VERI 5
- NGNE 8
- Target Price
- VERI $10.40
- NGNE $44.75
- AVG Volume (30 Days)
- VERI 10.2M
- NGNE 252.5K
- Earning Date
- VERI 11-06-2025
- NGNE 11-18-2025
- Dividend Yield
- VERI N/A
- NGNE N/A
- EPS Growth
- VERI N/A
- NGNE N/A
- EPS
- VERI N/A
- NGNE N/A
- Revenue
- VERI $90,902,000.00
- NGNE N/A
- Revenue This Year
- VERI $19.12
- NGNE N/A
- Revenue Next Year
- VERI $18.83
- NGNE N/A
- P/E Ratio
- VERI N/A
- NGNE N/A
- Revenue Growth
- VERI N/A
- NGNE N/A
- 52 Week Low
- VERI $1.22
- NGNE $6.88
- 52 Week High
- VERI $9.42
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- VERI 54.12
- NGNE 45.40
- Support Level
- VERI $5.95
- NGNE $27.28
- Resistance Level
- VERI $6.72
- NGNE $32.99
- Average True Range (ATR)
- VERI 0.61
- NGNE 3.22
- MACD
- VERI -0.08
- NGNE -0.88
- Stochastic Oscillator
- VERI 44.68
- NGNE 17.44
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.